Jeffrey H. Murray

Array ( [id] => 15850469 [patent_doc_number] => 10640500 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-05-05 [patent_title] => Tetrahydropyrazolopyrimidine compounds [patent_app_type] => utility [patent_app_number] => 15/841767 [patent_app_country] => US [patent_app_date] => 2017-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 80 [patent_figures_cnt] => 93 [patent_no_of_words] => 30696 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 1291 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15841767 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12624390 [patent_doc_number] => 20180099960 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-12 [patent_title] => PROTEIN KINASE INHIBITORS [patent_app_type] => utility [patent_app_number] => 15/839332 [patent_app_country] => US [patent_app_date] => 2017-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16886 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15839332 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16969311 [patent_doc_number] => 11065257 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-07-20 [patent_title] => Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors [patent_app_type] => utility [patent_app_number] => 16/468444 [patent_app_country] => US [patent_app_date] => 2017-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16458 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 186 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16468444 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12706864 [patent_doc_number] => 20180127454 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-10 [patent_title] => COMPOSITIONS AND METHODS FOR ALTERING SECOND MESSENGER SIGNALING [patent_app_type] => utility [patent_app_number] => 15/836763 [patent_app_country] => US [patent_app_date] => 2017-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39145 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15836763 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12616077 [patent_doc_number] => 20180097189 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-05 [patent_title] => ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME [patent_app_type] => utility [patent_app_number] => 15/830178 [patent_app_country] => US [patent_app_date] => 2017-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20445 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 692 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15830178 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12260533 [patent_doc_number] => 20180079730 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-22 [patent_title] => 'ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES' [patent_app_type] => utility [patent_app_number] => 15/829028 [patent_app_country] => US [patent_app_date] => 2017-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 14129 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15829028 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15132709 [patent_doc_number] => 10479801 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-11-19 [patent_title] => Tetracyclic heterocycle compounds useful as HIV integrase inhibitors [patent_app_type] => utility [patent_app_number] => 15/826898 [patent_app_country] => US [patent_app_date] => 2017-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49728 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15826898 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12584679 [patent_doc_number] => 20180086722 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-29 [patent_title] => PROCESSES FOR THE PREPARATION OF PYRIMIDINYLCYCLOPENTANE COMPOUNDS [patent_app_type] => utility [patent_app_number] => 15/827985 [patent_app_country] => US [patent_app_date] => 2017-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17003 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15827985 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12786178 [patent_doc_number] => 20180153895 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-07 [patent_title] => Crystalline Forms of Ibrutinib [patent_app_type] => utility [patent_app_number] => 15/827471 [patent_app_country] => US [patent_app_date] => 2017-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6161 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15827471 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16206424 [patent_doc_number] => 20200239414 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-30 [patent_title] => PROCESS FOR THE PREPARATION OF FREEZE-DRIED 2-[(3-AMINOPROPYL)AMINO]ETHANETHIOL FORMULATION [patent_app_type] => utility [patent_app_number] => 16/465505 [patent_app_country] => US [patent_app_date] => 2017-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9274 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16465505 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15293465 [patent_doc_number] => 20190389868 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-26 [patent_title] => COMPOUNDS AND THEIR METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/464483 [patent_app_country] => US [patent_app_date] => 2017-11-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30680 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -84 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16464483 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14836125 [patent_doc_number] => 20190276463 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-12 [patent_title] => GSK-3 INHIBITORS [patent_app_type] => utility [patent_app_number] => 16/463451 [patent_app_country] => US [patent_app_date] => 2017-11-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20973 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16463451 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15070933 [patent_doc_number] => 10464942 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-11-05 [patent_title] => Process for the manufacture of ixabepilone [patent_app_type] => utility [patent_app_number] => 15/817487 [patent_app_country] => US [patent_app_date] => 2017-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 8020 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 171 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15817487 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14145349 [patent_doc_number] => 10253033 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-04-09 [patent_title] => De novo synthesis of bacteriochlorins [patent_app_type] => utility [patent_app_number] => 15/817973 [patent_app_country] => US [patent_app_date] => 2017-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 5 [patent_no_of_words] => 26449 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 368 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15817973 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14294369 [patent_doc_number] => 10287300 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-05-14 [patent_title] => Heterocyclic derivatives as modulators of kinase activity [patent_app_type] => utility [patent_app_number] => 15/818035 [patent_app_country] => US [patent_app_date] => 2017-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16564 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 269 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15818035 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12750361 [patent_doc_number] => 20180141954 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-24 [patent_title] => PYRROLOPYRIMIDINES AS CFTR POTENTIATORS [patent_app_type] => utility [patent_app_number] => 15/815809 [patent_app_country] => US [patent_app_date] => 2017-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 59238 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15815809 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14836085 [patent_doc_number] => 20190276443 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-12 [patent_title] => INDOLE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 [patent_app_type] => utility [patent_app_number] => 16/461880 [patent_app_country] => US [patent_app_date] => 2017-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11897 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 142 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16461880 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17015192 [patent_doc_number] => 11084818 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-10 [patent_title] => Nitrogen-containing heterocyclic compound, preparation method, intermediate, pharmaceutical composition and use [patent_app_type] => utility [patent_app_number] => 16/348504 [patent_app_country] => US [patent_app_date] => 2017-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25564 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 649 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16348504 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15589567 [patent_doc_number] => 20200071318 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-05 [patent_title] => SGC STIMULATORS [patent_app_type] => utility [patent_app_number] => 16/348377 [patent_app_country] => US [patent_app_date] => 2017-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54734 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16348377 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14277035 [patent_doc_number] => 20190135802 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-09 [patent_title] => MODULATION OF N-ACYLETHANOLAMINE-HYDROLYSING ACID AMIDASE (NAAA) FOR DISEASE TREATMENT [patent_app_type] => utility [patent_app_number] => 15/803379 [patent_app_country] => US [patent_app_date] => 2017-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3405 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15803379 [rel_patent_id] =>[rel_patent_doc_number] =>)